ClinicalTrials.Veeva
Menu

Find clinical trials for Adenocarcinoma in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Carcinoma
Cancer
Pancreatic Cancer
Colorectal Cancer
Stomach Cancer
Prostatic Cancer
Esophageal Cancer

Adenocarcinoma trials near Paris, Île-de-France, FRA:

Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

with HER2-positive gastric or gastro-esophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regim...

Enrolling
Gastric Cancer, Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Ramucirumab
Drug: Paclitaxel

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Paris, France and 157 other locations

Oxaliplatin ± nivolumab in combination with trifluridine/tipiracil or 5-fluorouracile (5-FU) in frail patients with advanced, recurrent or metastatic...

Enrolling
Esophagus Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Drug: Oxaliplatin
Drug: Nivolumab

Phase 2

Unicancer
Unicancer

Paris, France and 26 other locations

for front line treatment of locally-advanced pancreatic adenocarcinoma.The device is an experimental, portable, battery operated device for ...

Active, not recruiting
Pancreas Adenocarcinoma
Drug: Gemcitabine
Drug: nab paclitaxel

Phase 3

NovoCure
NovoCure

Paris, France and 197 other locations

mFOLFIRINOX in the treatment of locally advanced pancreatic ductal adenocarcinoma.The study drug which is tested is the NP137 in association...

Enrolling
Pancreatic Ductal Adenocarcinoma
Drug: Calcium levofolinate
Drug: Oxaliplatin

Phase 1

Grenoble Alpes University Hospital Center (CHU)
Grenoble Alpes University Hospital Center (CHU)

Paris, France and 8 other locations

Phase 1b/2 study to assess the safety and efficacy of mitazalimab in combination with chemotherapy in patients with metastatic pancreatic ductal adenocarcinoma...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Biological: CD40 agonist mitazalimab in combination with chemotherapy

Phase 1, Phase 2

Alligator Bioscience

Paris, France and 13 other locations

and placebo in first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).This study aims to explore whether blockade of Transforming Gr...

Active, not recruiting
Metastatic Pancreatic Ductal Adenocarcinoma
Drug: Nab-paclitaxel
Drug: Gemcitabine

Phase 3

Novartis
Novartis

Paris, France and 113 other locations

TEDOPAM is a randomized (1.1.1) non-comparative phase II study. This study will assess the efficacy and safety of OSE2101 alone or in combination wit...

Enrolling
Pancreatic Ductal Adenocarcinoma
Metastatic Cancer
Drug: OSE2101
Drug: FOLFIRI

Phase 2

GERCOR - Multidisciplinary Oncology Cooperative Group

Paris, France and 27 other locations

Gastric adenocarcinoma is the 4th most frequent cancer and the 2nd leading cause of cancer mortality. Most of the patients have metastatic, ...

Active, not recruiting
Gastric Adenocarcinoma
Gastric Cancer
Drug: Durvalumab
Drug: Tremelimumab

Phase 2

Federation Francophone de Cancerologie Digestive

Paris, France and 34 other locations

mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC) who have not received prior systemic anti-cancer tre...

Enrolling
Adenocarcinoma, Pancreatic Ductal
Drug: mFOLFIRINOX
Drug: Autogene cevumeran

Phase 2

Genentech
Genentech

Villejuif, France and 38 other locations

The purpose of this study is to determine the Objective Response Rate (ORR) of zolbetuzimab as a single agent as assessed by an independent central r...

Enrolling
Pharmacokinetics of Oxaliplatin
Pharmacokinetics of Zolbetuximab
Drug: folinic acid
Drug: fluorouracil

Phase 2

Astellas
Astellas

Paris, France and 25 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems